Protecting Access to Medication Abortion Act of 2023

HR 767 modifies the FDA's safety program for mifepristone (a medication used in medication abortion) to improve access. It requires the FDA to remove in-person dispensing rules, allow prescriptions via telehealth, and permit certified pharmacies to mail the medication directly to patients. This bill directly affects patients seeking medication abortion and healthcare providers who prescribe or dispense mifepristone. The changes apply specifically to mifepristone's safety program under federal law, ensuring broader access through existing pharmacy channels.